Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

JERUSALEM, Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today that Dr. Jonathan Sadeh has been appointed as a member of the Company's Scientific Advisory Board (SAB). In this capacity, Dr Sadeh will play a significant role in advancing the clinical development of Scinai's lead IL-17 program along with other promising assets in their unique VHH antibody pipeline.